Anlon Healthcare Ltd IPO

Anlon Healthcare Ltd Mainboard IPO is going to hit the market on 26 August 2025 and closes on 29 August 2025. The price band for the issue has been fixed at ₹86 to ₹91 per share. The lot size for applying for the IPO is 164 shares. One can apply for 1 lot (164 shares) and multiples thereof. Anlon Healthcare IPO minimum application amount is ₹14,924 for the retailer. The company will raise a total of ₹121.03 crore through a 100% fresh issue of 1.33 crore equity shares, without any offer-for-sale. The allotment on September 1, 2025 and listing on NSE and BSE on September 3, 2025. Interactive Financial Services is the lead manager of the issue and KFin Technologies is the registrar to the issue.

Company Background

Anlon Healthcare Limited is a pharmaceutical manufacturer for the Indian formulators and export market and has its headquarters in Rajkot, Gujarat with the business being founded in 2013. The company's emphasis on process chemistry, documentation and adherence to global pharmacopeias, GMP-aligned systems in the product scaling and geography coverage scalability of the company. Conversion from a private to a public company in 2024 is also covered in the draft red herring prospectus, before its August 2025 listing timetable.

Operations & Product Range

Facility & Production

The organisation has multipurpose, GMP-compliant facilities around Rajkot, equipped to manage lab-to-plant scale-up and commercial production requirements, backed by utilities including solvent recovery and effluent treatment and QC instrumentation (HPLC/GC and wet labs) in line with statements made around API/intermediate production readiness. The process engineering team optimises the route, the impurity profile and the documentation so that technology transfers and validations can be conducted for both the client and various regulatory audits in India and certain export markets.

Brands & Market Presence

Being a B2B API/intermediates supplier, Anlon is not a consumer-facing name brand. Its “market presence” is primarily apparent in customer audits, DMF/documentation pathways and supply track records with domestic formulators and buyers in export markets, where purchasing teams assess quality systems and dossier completeness rather than retail brand identity.

Revenue Channels

• Supply of APIs & Intermediates to Indian Formulation Companies on a contractual basis/orders.
• Export sales into semi-regulated and regulated markets through documentation-backed SKUs.
• Custom synthesis /contract manufacturing for distinctive intermediates/APIs for B2B partners.
• Working capital-based scaling of volumes up with existing customers as new products are qualified.

Management & Shareholding

Promoters & Shareholding

The promoter group remains the majority owner pre-IPO(around 70.26%), which will be diluted proportionately with the fresh issue, yet they will drive strategic planning, capacity investment and regulatory filings, even as the company ramps up export-facing documentations and deliveries.

Board Members

The board is made up of executive directors from operations and strategy, as well as independent directors offering governance, finance and risk views. They serve to ensure that the company's internal controls and disclosures are consistent with the requirements of the mainboard listing.